Targeting mitochondria for cancer therapy (original) (raw)

• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  CAS PubMed Google Scholar
• Fulda, S. Tumor resistance to apoptosis. Int. J. Cancer 124, 511–515 (2009).
  CAS PubMed Google Scholar
• Fulda, S. & Debatin, K. M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798–4811 (2006).
  CAS PubMed Google Scholar
• Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99–163 (2007).
  CAS PubMed Google Scholar
• Galluzzi, L. et al. No death without life: vital functions of apoptotic effectors. Cell Death Differ. 15, 1113–1123 (2008).
  CAS PubMed Google Scholar
• Galluzzi, L. & Kroemer, G. Necroptosis: a specialized pathway of programmed necrosis. Cell 135, 1161–1163 (2008).
  CAS PubMed Google Scholar
• Golstein, P. & Kroemer, G. Cell death by necrosis: towards a molecular definition. Trends Biochem. Sci. 32, 37–43 (2007).
  CAS PubMed Google Scholar
• Gogvadze, V., Orrenius, S. & Zhivotovsky, B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 18, 165–173 (2008).
  CAS PubMed Google Scholar
• Bellance, N., Lestienne, P. & Rossignol, R. Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front. Biosci. 14, 4015–4034 (2009).
  Google Scholar
• Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780–783 (2009). First demonstration that breast cancer stem cells maintain lower levels of ROS than their non-tumorigenic counterparts, providing a link between the management of ROS by cancer stem cells and tumour resistance to radiotherapy.
  CAS PubMed PubMed Central Google Scholar
• Kroemer, G. & Pouyssegur, J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472–482 (2008).
  Article CAS PubMed Google Scholar
• Modica-Napolitano, J. S. & Singh, K. K. Mitochondrial dysfunction in cancer. Mitochondrion 4, 755–762 (2004).
  CAS PubMed Google Scholar
• Canter, J. A., Kallianpur, A. R., Parl, F. F. & Millikan, R. C. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res. 65, 8028–8033 (2005).
  CAS PubMed Google Scholar
• Petros, J. A. et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl Acad. Sci. USA 102, 719–724 (2005).
  CAS PubMed PubMed Central Google Scholar
• Galluzzi, L. et al. Mitochondrial gateways to cancer. Mol. Aspects Med. 31, 1–20 (2010).
  CAS PubMed Google Scholar
• Armstrong, J. S. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br. J. Pharmacol. 151, 1154–1165 (2007).
  CAS PubMed PubMed Central Google Scholar
• Galluzzi, L., Larochette, N., Zamzami, N. & Kroemer, G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25, 4812–4830 (2006).
  CAS PubMed Google Scholar
• Gogvadze, V., Orrenius, S. & Zhivotovsky, B. Mitochondria as targets for cancer chemotherapy. Semin. Cancer Biol. 19, 57–66 (2009).
  CAS PubMed Google Scholar
• Bouchier-Hayes, L., Munoz-Pinedo, C., Connell, S. & Green, D. R. Measuring apoptosis at the single cell level. Methods 44, 222–228 (2008).
  CAS PubMed PubMed Central Google Scholar
• Nakagawa, T. et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434, 652–658 (2005).
  CAS PubMed Google Scholar
• Baines, C. P., Kaiser, R. A., Sheiko, T., Craigen, W. J. & Molkentin, J. D. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nature Cell Biol. 9, 550–555 (2007).
  CAS PubMed Google Scholar
• Galluzzi, L. & Kroemer, G. Mitochondrial apoptosis without VDAC. Nature Cell Biol. 9, 487–489 (2007).
  CAS PubMed Google Scholar
• Kokoszka, J. E. et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427, 461–465 (2004).
  CAS PubMed PubMed Central Google Scholar
• Majewski, N. et al. Hexokinase–mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell 16, 819–830 (2004).
  CAS PubMed Google Scholar
• Zamora, M., Granell, M., Mampel, T. & Vinas, O. Adenine nucleotide translocase 3 (ANT3) overexpression induces apoptosis in cultured cells. FEBS Lett. 563, 155–160 (2004).
  CAS PubMed Google Scholar
• Bauer, M. K., Schubert, A., Rocks, O. & Grimm, S. Adenine nucleotide translocase-1, a component of the permeability transition pore, can dominantly induce apoptosis. J. Cell Biol. 147, 1493–1502 (1999).
  CAS PubMed PubMed Central Google Scholar
• Le Bras., M. et al. Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res. 66, 9143–9152 (2006).
  CAS PubMed Google Scholar
• Marzo, I. et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 281, 2027–2031 (1998).
  CAS PubMed Google Scholar
• Belzacq, A. S. et al. Bcl-2 and Bax modulate adenine nucleotide translocase activity. Cancer Res. 63, 541–546 (2003).
  CAS PubMed Google Scholar
• Shen, Q. et al. Adenine nucleotide translocator cooperates with core cell death machinery to promote apoptosis in Caenorhabditis elegans. Mol. Cell Biol. 29, 3881–3893 (2009).
  CAS PubMed PubMed Central Google Scholar
• Zhivotovsky, B., Galluzzi, L., Kepp, O. & Kroemer, G. Adenine nucleotide translocase: a component of the phylogenetically conserved cell death machinery. Cell Death Differ. 16, 1419–1425 (2009).
  CAS PubMed Google Scholar
• Don, A. S. et al. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 3, 497–509 (2003). Demonstrates that GSAO, a peptide trivalent arsenical that acts as an ANT cross-linker, inhibits tumour angiogenesis by selectively targeting mitochondria in proliferating endothelial cells.
  CAS PubMed Google Scholar
• Belzacq, A. S. et al. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 20, 7579–7587 (2001).
  CAS PubMed Google Scholar
• Oudard, S. et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 63, 81–86 (2003).
  PubMed Google Scholar
• Dogliotti, L. et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J. Clin. Oncol. 14, 1165–1172 (1996).
  CAS PubMed Google Scholar
• Papaldo, P. et al. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J. Clin. Oncol. 21, 3462–3468 (2003).
  CAS PubMed Google Scholar
• Lehenkari, P. P. et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 61, 1255–1262 (2002).
  CAS PubMed Google Scholar
• Diel, I. J. et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann. Oncol. 19, 2007–2011 (2008).
  CAS PubMed PubMed Central Google Scholar
• Green, J. R. Antitumor effects of bisphosphonates. Cancer 97, 840–847 (2003).
  PubMed Google Scholar
• Tang, X. et al. Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1α/VEGF signaling pathways in human breast cancer cells. Int. J. Cancer 126, 90–103 (2010).
  CAS PubMed PubMed Central Google Scholar
• Slack, J. L. & Rusiniak, M. E. Current issues in the management of acute promyelocytic leukemia. Ann. Hematol. 79, 227–238 (2000).
  CAS PubMed Google Scholar
• Marchetti, P. et al. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res. 59, 6257–6266 (1999).
  CAS PubMed Google Scholar
• Notario, B., Zamora, M., Vinas, O. & Mampel, T. All-_trans_-retinoic acid binds to and inhibits adenine nucleotide translocase and induces mitochondrial permeability transition. Mol. Pharmacol. 63, 224–231 (2003).
  CAS PubMed Google Scholar
• Parrella, E. et al. Antitumor activity of the retinoid-related molecules (E)-3-(4′-hydroxy-3′-adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma: role of retinoic acid receptor γ and retinoid-independent pathways. Mol. Pharmacol. 70, 909–924 (2006).
  CAS PubMed Google Scholar
• Sala, F. et al. Development and validation of a liquid chromatography–tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 3118–3126 (2009).
  CAS PubMed Google Scholar
• Maaser, K. et al. Up-regulation of the peripheral benzodiazepine receptor during human colorectal carcinogenesis and tumor spread. Clin. Cancer Res. 11, 1751–1756 (2005).
  CAS PubMed Google Scholar
• Galiegue, S., Casellas, P., Kramar, A., Tinel, N. & Simony-Lafontaine, J. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin. Cancer Res. 10, 2058–2064 (2004).
  CAS PubMed Google Scholar
• Okaro, A. C., Fennell, D. A., Corbo, M., Davidson, B. R. & Cotter, F. E. Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-XL and Mcl-1 expressing human cholangiocarcinoma cells. Gut 51, 556–561 (2002).
  CAS PubMed PubMed Central Google Scholar
• Decaudin, D. et al. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res. 62, 1388–1393 (2002).
  CAS PubMed Google Scholar
• Gonzalez-Polo, R. A. et al. PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene 24, 7503–7513 (2005).
  CAS PubMed Google Scholar
• Walter, R. B. et al. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood 106, 3584–3593 (2005).
  CAS PubMed PubMed Central Google Scholar
• Palmeira, C. M. & Wallace, K. B. Benzoquinone inhibits the voltage-dependent induction of the mitochondrial permeability transition caused by redox-cycling naphthoquinones. Toxicol. Appl. Pharmacol. 143, 338–347 (1997).
  CAS PubMed Google Scholar
• Petronilli, V. et al. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents. J. Biol. Chem. 269, 16638–16642 (1994).
  CAS PubMed Google Scholar
• Costantini, P. et al. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 19, 307–314 (2000).
  CAS PubMed Google Scholar
• Lim, D. et al. Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Invest. New Drugs 23, 235–239 (2005).
  PubMed Google Scholar
• Sarin, S. K. et al. High dose vitamin K3 infusion in advanced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 21, 1478–1482 (2006).
  CAS PubMed Google Scholar
• Magda, D. & Miller, R. A. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin. Cancer Biol. 16, 466–476 (2006).
  CAS PubMed Google Scholar
• Mehta, M. P. et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int. J. Radiat. Oncol. Biol. Phys. 73, 1069–1076 (2009).
  CAS PubMed Google Scholar
• Bradley, K. A. et al. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol. 10, 752–758 (2008).
  CAS PubMed PubMed Central Google Scholar
• Bey, E. A. et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone. Proc. Natl Acad. Sci. USA 104, 11832–11837 (2007).
  CAS PubMed PubMed Central Google Scholar
• Maeda, H. et al. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ. 11, 737–746 (2004).
  CAS PubMed Google Scholar
• Dragovich, T. et al. Phase I trial of imexon in patients with advanced malignancy. J. Clin. Oncol. 25, 1779–1784 (2007).
  CAS PubMed Google Scholar
• Moulder, S. et al. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest. New Drugs 6 Jun 2009 (doi:10.1007/s10637-009-9273-1).
  PubMed Google Scholar
• Trachootham, D. et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 10, 241–252 (2006). Demonstrates that abnormal ROS generation in tumour cells can be exploited for selectively killing cancer versus normal cells by means of the natural compound PEITC.
  CAS PubMed Google Scholar
• Xiao, D. et al. Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis 27, 2223–2234 (2006).
  CAS PubMed Google Scholar
• Alexandre, J. et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J. Natl Cancer Inst. 98, 236–244 (2006).
  CAS PubMed Google Scholar
• Huang, P., Feng, L., Oldham, E. A., Keating, M. J. & Plunkett, W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407, 390–395 (2000).
  CAS PubMed Google Scholar
• Wood, L. et al. Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure–activity relationships. Anticancer Drug Des. 16, 209–215 (2001).
  CAS PubMed Google Scholar
• Juarez, J. C. et al. Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc. Natl Acad. Sci. USA 105, 7147–7152 (2008).
  CAS PubMed PubMed Central Google Scholar
• Lu, J., Chew, E. H. & Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl Acad. Sci. USA 104, 12288–12293 (2007).
  CAS PubMed PubMed Central Google Scholar
• Tuma, R. S. Reactive oxygen species may have antitumor activity in metastatic melanoma. J. Natl Cancer Inst. 100, 11–12 (2008).
  PubMed Google Scholar
• Matei, D. et al. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol. Oncol. 115, 90–96 (2009).
  CAS PubMed Google Scholar
• Tevaarwerk, A. J. et al. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin. Cancer Res. 15, 1460–1465 (2009).
  CAS PubMed PubMed Central Google Scholar
• Rajkumar, S. V. et al. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin. Cancer Res. 13, 6162–6167 (2007).
  CAS PubMed Google Scholar
• Sweeney, C. et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin. Cancer Res. 11, 6625–6633 (2005).
  CAS PubMed Google Scholar
• O'Day, S. et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J. Clin. Oncol. 27, 5452–5458 (2009).
  CAS PubMed Google Scholar
• Berkenblit, A. et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin. Cancer Res. 13, 584–590 (2007).
  CAS PubMed Google Scholar
• Chipuk, J. E., Bouchier-Hayes, L. & Green, D. R. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ. 13, 1396–1402 (2006).
  CAS PubMed Google Scholar
• Willis, S. N. & Adams, J. M. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17, 617–625 (2005).
  CAS PubMed PubMed Central Google Scholar
• Lovell, J. F. et al. Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135, 1074–1084 (2008).
  CAS PubMed Google Scholar
• Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E. & George, D. L. Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex. Nature Cell Biol. 6, 443–450 (2004).
  CAS PubMed Google Scholar
• Chipuk, J. E. et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010–1014 (2004).
  CAS PubMed Google Scholar
• Gavathiotis, E. et al. BAX activation is initiated at a novel interaction site. Nature 455, 1076–1081 (2008).
  CAS PubMed PubMed Central Google Scholar
• Bellot, G. et al. TOM22, a core component of the mitochondria outer membrane protein translocation pore, is a mitochondrial receptor for the proapoptotic protein Bax. Cell Death Differ. 14, 785–794 (2007).
  CAS PubMed Google Scholar
• Ross, K., Rudel, T. & Kozjak-Pavlovic, V. TOM-independent complex formation of Bax and Bak in mammalian mitochondria during TNFα-induced apoptosis. Cell Death Differ. 16, 697–707 (2009).
  CAS PubMed Google Scholar
• Rostovtseva, T. K. et al. Bax activates endophilin B1 oligomerization and lipid membrane vesiculation. J. Biol. Chem. 284, 34390–34399 (2009).
  CAS PubMed PubMed Central Google Scholar
• Kuwana, T. et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111, 331–342 (2002).
  CAS PubMed Google Scholar
• Lucken-Ardjomande, S., Montessuit, S. & Martinou, J. C. Contributions to Bax insertion and oligomerization of lipids of the mitochondrial outer membrane. Cell Death Differ. 15, 929–937 (2008).
  CAS PubMed Google Scholar
• Cipolat, S. et al. Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling. Cell 126, 163–175 (2006).
  CAS PubMed Google Scholar
• Frezza, C. et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 126, 177–189 (2006).
  CAS PubMed Google Scholar
• Lessene, G., Czabotar, P. E. & Colman, P. M. BCL-2 family antagonists for cancer therapy. Nature Rev. Drug Discov. 7, 989–1000 (2008).
  CAS Google Scholar
• Vogler, M., Dinsdale, D., Dyer, M. J. & Cohen, G. M. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 16, 360–367 (2009).
  CAS PubMed Google Scholar
• Vogler, M. et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 16, 1030–1039 (2009).
  CAS PubMed Google Scholar
• Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005). Describes the discovery of ABT-737, an inhibitor of BCL-2, BCL-X L and BCL-W, by nuclear magnetic resonance-based screening, parallel synthesis and structure-based design.
  CAS PubMed Google Scholar
• Chen, S., Dai, Y., Harada, H., Dent, P. & Grant, S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 67, 782–791 (2007).
  CAS PubMed Google Scholar
• Konopleva, M. et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375–388 (2006).
  CAS PubMed Google Scholar
• Mason, K. D. et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc. Natl Acad. Sci. USA 105, 17961–17966 (2008).
  CAS PubMed PubMed Central Google Scholar
• van Delft, M. F. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389–399 (2006).
  CAS PubMed PubMed Central Google Scholar
• Kang, M. H. et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110, 2057–2066 (2007).
  CAS PubMed Google Scholar
• Kutuk, O. & Letai, A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 68, 7985–7994 (2008).
  CAS PubMed PubMed Central Google Scholar
• Hann, C. L. et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 68, 2321–2328 (2008).
  CAS PubMed PubMed Central Google Scholar
• Tagscherer, K. E. et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27, 6646–6656 (2008).
  CAS PubMed Google Scholar
• Kuroda, J. et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl Acad. Sci. USA 103, 14907–14912 (2006).
  CAS PubMed PubMed Central Google Scholar
• Kuroda, J. et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr–Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr–Abl-positive leukemia. Cell Death Differ. 14, 1667–1677 (2007).
  CAS PubMed Google Scholar
• Kohl, T. M. et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 21, 1763–1772 (2007).
  CAS PubMed Google Scholar
• Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. & Strasser, A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 4, e316 (2007).
  PubMed Central Google Scholar
• Gong, Y. et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 4, e294 (2007).
  PubMed PubMed Central Google Scholar
• Cragg, M. S. et al. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest. 118, 3651–3659 (2008).
  CAS PubMed PubMed Central Google Scholar
• Paoluzzi, L. et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112, 2906–2916 (2008).
  CAS PubMed Google Scholar
• Miller, L. A. et al. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J. Invest. Dermatol. 129, 964–971 (2009).
  CAS PubMed Google Scholar
• Whitecross, K. F. et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 113, 1982–1991 (2009).
  CAS PubMed Google Scholar
• Huang, S. & Sinicrope, F. A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 68, 2944–2951 (2008).
  CAS PubMed PubMed Central Google Scholar
• Song, J. H., Kandasamy, K. & Kraft, A. S. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J. Biol. Chem. 283, 25003–25013 (2008).
  CAS PubMed PubMed Central Google Scholar
• Mason, K. D. et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 23, 2034–2041 (2009).
  CAS PubMed Google Scholar
• Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008).
  CAS PubMed Google Scholar
• Lock, R. et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr. Blood Cancer 50, 1181–1189 (2008).
  PubMed Google Scholar
• Shoemaker, A. R. et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res. 66, 8731–8739 (2006).
  CAS PubMed Google Scholar
• Lynn, A. & Jones, L. Gossypol and some other terpenoids, flavonoids, and phenols that affect quality of cottonseed protein. Am. Oil Chemists Soc. 56, 727–730 (1979).
  Google Scholar
• Azmi, A. S. & Mohammad, R. M. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J. Cell Physiol. 218, 13–21 (2009).
  CAS PubMed PubMed Central Google Scholar
• Liu, G. et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin. Cancer Res. 15, 3172–3176 (2009).
  CAS PubMed PubMed Central Google Scholar
• Kitada, S. et al. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 111, 3211–3219 (2008).
  CAS PubMed PubMed Central Google Scholar
• Nguyen, M. et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl Acad. Sci. USA 104, 19512–19517 (2007). First demonstration that obatoclax triggers apoptosis by neutralizing MCL1.
  CAS PubMed PubMed Central Google Scholar
• Trudel, S. et al. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109, 5430–5438 (2007).
  CAS PubMed Google Scholar
• Perez-Galan, P., Roue, G., Villamor, N., Campo, E. & Colomer, D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109, 4441–4449 (2007).
  CAS PubMed Google Scholar
• Konopleva, M. et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 68, 3413–3420 (2008).
  CAS PubMed PubMed Central Google Scholar
• O'Brien, S. M. et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113, 299–305 (2009).
  CAS PubMed PubMed Central Google Scholar
• Schimmer, A. D. et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 8295–8301 (2008).
  CAS PubMed Google Scholar
• Wang, J. L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 97, 7124–7129 (2000).
  CAS PubMed PubMed Central Google Scholar
• Manero, F. et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res. 66, 2757–2764 (2006).
  CAS PubMed Google Scholar
• Moulder, S. L. et al. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin. Cancer Res. 14, 7909–7916 (2008).
  CAS PubMed PubMed Central Google Scholar
• O'Brien, S. et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 25, 1114–1120 (2007).
  CAS PubMed Google Scholar
• Rheingold, S. R. et al. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J. Clin. Oncol. 25, 1512–1518 (2007).
  CAS PubMed Google Scholar
• Rudin, C. M. et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J. Clin. Oncol. 26, 870–876 (2008).
  CAS PubMed Google Scholar
• Chanan-Khan, A. A. et al. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk. Lymphoma 50, 559–565 (2009).
  CAS PubMed Google Scholar
• Simons, A. L., Ahmad, I. M., Mattson, D. M., Dornfeld, K. J. & Spitz, D. R. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 67, 3364–3370 (2007).
  CAS PubMed Google Scholar
• Pastorino, J. G., Hoek, J. B. & Shulga, N. Activation of glycogen synthase kinase 3β disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res. 65, 10545–10554 (2005).
  CAS PubMed Google Scholar
• Chiara, F. et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS One 3, e1852 (2008).
  PubMed PubMed Central Google Scholar
• Galluzzi, L., Kepp, O., Tajeddine, N. & Kroemer, G. Disruption of the hexokinase-VDAC complex for tumor therapy. Oncogene 27, 4633–4635 (2008).
  CAS PubMed Google Scholar
• Goldin, N. et al. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 27, 4636–4643 (2008).
  CAS PubMed Google Scholar
• Kim, W. et al. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol. Cancer Ther. 6, 2554–2562 (2007).
  CAS PubMed Google Scholar
• Cao, X. et al. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin. Cancer Res. 14, 1831–1839 (2008).
  CAS PubMed Google Scholar
• Chen, Z., Zhang, H., Lu, W. & Huang, P. Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim. Biophys. Acta 1787, 553–560 (2009).
  CAS PubMed PubMed Central Google Scholar
• Bonnet, S. et al. A mitochondria–K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11, 37–51 (2007). Proof-of-concept study that the PDK inhibitor dichloroacetate induces apoptosis by shifting metabolism from glycolysis to glucose oxidation (resulting in mitochondrial depolarization), and by upregulating the K+ channel Kv1.5.
  CAS PubMed Google Scholar
• Fantin, V. R., St-Pierre, J. & Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425–434 (2006).
  CAS PubMed Google Scholar
• Hatzivassiliou, G. et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311–321 (2005).
  CAS PubMed Google Scholar
• Wellen, K. E. et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076–1080 (2009). Identification of a novel molecular link between cellular metabolism and gene regulation through histone acetylation.
  CAS PubMed PubMed Central Google Scholar
• Beckers, A. et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 67, 8180–8187 (2007).
  CAS PubMed Google Scholar
• Carvalho, M. A. et al. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int. J. Cancer 123, 2557–2565 (2008).
  CAS PubMed Google Scholar
• Mootha, V. K. et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 115, 629–640 (2003).
  CAS PubMed Google Scholar
• Kang, B. H. et al. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131, 257–270 (2007).
  CAS PubMed Google Scholar
• Wright, G. L. et al. VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase. FASEB J. 22, 3264–3275 (2008).
  CAS PubMed PubMed Central Google Scholar
• Plescia, J. et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7, 457–468 (2005). Development of the first cell-permeable peptidomimetic that disrupts the interaction between the chaperone HSP90 and the anti-apoptotic and mitotic regulator survivin.
  CAS PubMed Google Scholar
• Gyurkocza, B. et al. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J. Natl Cancer Inst. 98, 1068–1077 (2006).
  CAS PubMed Google Scholar
• Kang, B. H. et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 119, 454–464 (2009).
  CAS PubMed PubMed Central Google Scholar
• Rodina, A. et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nature Chem. Biol. 3, 498–507 (2007).
  CAS Google Scholar
• Caldas-Lopes, E. et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl Acad. Sci. USA 106, 8368–8373 (2009).
  CAS PubMed PubMed Central Google Scholar
• Paduch, R., Kandefer-Szerszen, M., Trytek, M. & Fiedurek, J. Terpenes: substances useful in human healthcare. Arch. Immunol. Ther. Exp. (Warsz) 55, 315–327 (2007).
  CAS Google Scholar
• Liby, K. T., Yore, M. M. & Sporn, M. B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nature Rev. Cancer 7, 357–369 (2007).
  CAS Google Scholar
• Cichewicz, R. H. & Kouzi, S. A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev. 24, 90–114 (2004).
  CAS PubMed Google Scholar
• Fulda, S. et al. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 57, 4956–4964 (1997).
  CAS PubMed Google Scholar
• Fulda, S. et al. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J. Biol. Chem. 273, 33942–33948 (1998).
  CAS PubMed Google Scholar
• Fulda, S., Susin, S. A., Kroemer, G. & Debatin, K. M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. 58, 4453–4460 (1998).
  CAS PubMed Google Scholar
• Andre, N. et al. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett. 532, 256–260 (2002).
  CAS PubMed Google Scholar
• Wick, W., Grimmel, C., Wagenknecht, B., Dichgans, J. & Weller, M. Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J. Pharmacol. Exp. Ther. 289, 1306–1312 (1999).
  CAS Google Scholar
• Tan, Y., Yu, R. & Pezzuto, J. M. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin. Cancer Res. 9, 2866–2875 (2003).
  CAS PubMed Google Scholar
• Selzer, E. et al. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J. Invest. Dermatol. 114, 935–940 (2000).
  CAS PubMed Google Scholar
• Selzer, E. et al. Betulinic acid-induced Mcl-1 expression in human melanoma — mode of action and functional significance. Mol. Med. 8, 877–884 (2002).
  CAS PubMed PubMed Central Google Scholar
• Thurnher, D. et al. Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. Head Neck 25, 732–740 (2003).
  PubMed Google Scholar
• Fulda, S. & Debatin, K. M. Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med. Pediatr. Oncol. 35, 616–618 (2000).
  CAS PubMed Google Scholar
• Meng, R. D. & El-Deiry, W. S. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp. Cell Res. 262, 154–169 (2001).
  CAS PubMed Google Scholar
• Salti, G. I. et al. Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent. Melanoma Res. 11, 99–104 (2001).
  CAS PubMed Google Scholar
• Zuco, V. et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett. 175, 17–25 (2002).
  CAS PubMed Google Scholar
• Lagouge, M. et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127, 1109–1122 (2006).
  CAS PubMed Google Scholar
• Gledhill, J. R., Montgomery, M. G., Leslie, A. G. & Walker, J. E. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl Acad. Sci. USA 104, 13632–13637 (2007).
  CAS PubMed PubMed Central Google Scholar
• Tinhofer, I. et al. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J. 15, 1613–1615 (2001).
  CAS PubMed Google Scholar
• Chen, C. et al. Mitochondrial ATP synthasome: three-dimensional structure by electron microscopy of the ATP synthase in complex formation with carriers for Pi and ADP/ATP. J. Biol. Chem. 279, 31761–31768 (2004).
  CAS PubMed Google Scholar
• Biasutto, L. et al. Development of mitochondria-targeted derivatives of resveratrol. Bioorg Med. Chem. Lett. 18, 5594–5597 (2008).
  CAS PubMed Google Scholar
• Jeong, S. H. et al. A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Biochem. Pharmacol. 77, 1337–1347 (2009).
  CAS PubMed Google Scholar
• Morrison, D. K. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol. 19, 16–23 (2009).
  CAS PubMed Google Scholar
• Korsmeyer, S. J. BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 59, 1693s–1700s (1999).
  CAS PubMed Google Scholar
• Boocock, D. J. et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16, 1246–1252 (2007).
  CAS PubMed Google Scholar
• Constantinou, C., Papas, A. & Constantinou, A. I. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int. J. Cancer 123, 739–752 (2008).
  CAS PubMed Google Scholar
• Zhao, Y., Neuzil, J. & Wu, K. Vitamin E analogues as mitochondria-targeting compounds: from the bench to the bedside? Mol. Nutr. Food Res. 53, 129–139 (2009).
  CAS PubMed Google Scholar
• Jia, L., Yu, W., Wang, P., Sanders, B. G. & Kline, K. In vivo and in vitro studies of anticancer actions of α-TEA for human prostate cancer cells. Prostate 68, 849–860 (2008).
  CAS PubMed Google Scholar
• Hahn, T. et al. Dietary administration of the proapoptotic vitamin E analogue α-tocopheryloxyacetic acid inhibits metastatic murine breast cancer. Cancer Res. 66, 9374–9378 (2006).
  CAS PubMed Google Scholar
• Lawson, K. A. et al. Comparison of vitamin E derivatives α-TEA and VES in reduction of mouse mammary tumor burden and metastasis. Exp. Biol. Med. (Maywood) 229, 954–963 (2004).
  CAS Google Scholar
• Dong, L. F. et al. Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene 27, 4324–4335 (2008). Identification of the interaction with the proximal and distal ubiquinone-binding sites of the respiratory complex II as the molecular basis for the mitochondrial targeting of α-TOS.
  CAS PubMed PubMed Central Google Scholar
• Dong, L. F. et al. Suppression of tumor growth in vivo by the mitocan α-tocopheryl succinate requires respiratory complex II. Clin. Cancer Res. 15, 1593–1600 (2009).
  CAS PubMed Google Scholar
• Dong, L. F. et al. Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res. 67, 11906–11913 (2007).
  CAS PubMed Google Scholar
• Neuzil, J. et al. Induction of cancer cell apoptosis by α-tocopheryl succinate: molecular pathways and structural requirements. FASEB J. 15, 403–415 (2001).
  CAS PubMed Google Scholar
• Fariss, M. W., Nicholls-Grzemski, F. A., Tirmenstein, M. A. & Zhang, J. G. Enhanced antioxidant and cytoprotective abilities of vitamin E succinate is associated with a rapid uptake advantage in rat hepatocytes and mitochondria. Free Radic. Biol. Med. 31, 530–541 (2001).
  CAS PubMed Google Scholar
• Wright, M. E. et al. Effects of α-tocopherol and β-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial. Cancer 109, 891–898 (2007).
  CAS PubMed Google Scholar
• Kim, J. H. et al. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Cancer Res. 65, 6312–6320 (2005).
  CAS PubMed Google Scholar
• Steele, A. J. et al. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia 20, 1073–1079 (2006).
  CAS PubMed Google Scholar
• Zhang, S., Ong, C. N. & Shen, H. M. Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. Cancer Lett. 211, 175–188 (2004).
  CAS PubMed Google Scholar
• Guzman, M. L. et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110, 4427–4435 (2007).
  CAS PubMed PubMed Central Google Scholar
• Guzman, M. L. et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105, 4163–4169 (2005).
  CAS PubMed PubMed Central Google Scholar
• Pajak, B., Gajkowska, B. & Orzechowski, A. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem. Cytobiol. 46, 129–135 (2008).
  CAS PubMed Google Scholar
• Rosen, J. M. & Jordan, C. T. The increasing complexity of the cancer stem cell paradigm. Science 324, 1670–1673 (2009).
  CAS PubMed PubMed Central Google Scholar
• Smith, J., Ladi, E., Mayer-Proschel, M. & Noble, M. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc. Natl Acad. Sci. USA 97, 10032–10037 (2000).
  CAS PubMed PubMed Central Google Scholar
• Tsatmali, M., Walcott, E. C. & Crossin, K. L. Newborn neurons acquire high levels of reactive oxygen species and increased mitochondrial proteins upon differentiation from progenitors. Brain Res. 1040, 137–150 (2005).
  CAS PubMed Google Scholar
• Ito, K. et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431, 997–1002 (2004).
  CAS PubMed Google Scholar
• Ito, K. et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nature Med. 12, 446–451 (2006).
  CAS PubMed Google Scholar
• Tothova, Z. et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128, 325–339 (2007).
  CAS PubMed Google Scholar
• Miyamoto, K. et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1, 101–112 (2007).
  CAS PubMed Google Scholar
• Simon, M. C. & Keith, B. The role of oxygen availability in embryonic development and stem cell function. Nature Rev. Mol. Cell Biol. 9, 285–296 (2008).
  CAS Google Scholar
• Brahimi-Horn, M. C., Chiche, J. & Pouyssegur, J. Hypoxia signalling controls metabolic demand. Curr. Opin. Cell Biol. 19, 223–229 (2007).
  CAS PubMed Google Scholar
• Warburg, O., Posener, K. & Negelein, E. Über den Stoffwechsel der Tumoren. Biochemische Zeitschrift 152, 319–344 (1924) (in German).
  Google Scholar
• Miyamoto, S., Murphy, A. N. & Brown, J. H. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ. 15, 521–529 (2008).
  CAS PubMed Google Scholar
• Manning, B. D. & Cantley, L. C. AKT/PKB signaling: navigating downstream. Cell 129, 1261–1274 (2007).
  CAS PubMed PubMed Central Google Scholar
• Wang, H. Q. et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24, 3574–3582 (2005).
  CAS PubMed Google Scholar
• Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M. & Cantley, L. C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181–186 (2008).
  CAS PubMed Google Scholar
• Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107–120 (2006).
  CAS PubMed Google Scholar
• Matoba, S. et al. p53 regulates mitochondrial respiration. Science 312, 1650–1653 (2006). This is the first demonstration that the absence of a single p53 target gene, synthesis of SCO2, recapitulates the metabolic switch towards glycolysis that is exhibited by p53-deficient cells, thereby providing a possible explanation for the Warburg effect.
  CAS PubMed Google Scholar
• Semenza, G. L. Life with oxygen. Science 318, 62–64 (2007).
  CAS PubMed Google Scholar
• Kim, J. W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell. Metab. 3, 177–185 (2006).
  PubMed Google Scholar
• Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L. & Denko, N. C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell. Metab. 3, 187–197 (2006).
  CAS PubMed Google Scholar
• Gottlieb, E. & Tomlinson, I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nature Rev. Cancer 5, 857–866 (2005).
  CAS Google Scholar
• Murphy, M. P. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol. 15, 326–330 (1997).
  CAS PubMed Google Scholar
• Galluzzi, L. et al. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 12, 803–813 (2007).
  CAS PubMed Google Scholar
• Yousif, L. F., Stewart, K. M. & Kelley, S. O. Targeting mitochondria with organelle-specific compounds: strategies and applications. Chembiochem 10, 1939–1950 (2009).
  CAS PubMed Google Scholar
• Ross, M. F., Filipovska, A., Smith, R. A., Gait, M. J. & Murphy, M. P. Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers. Biochem. J. 383, 457–468 (2004).
  CAS PubMed PubMed Central Google Scholar
• Kelso, G. F. et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J. Biol. Chem. 276, 4588–4596 (2001).
  CAS PubMed Google Scholar
• Yousif, L. F., Stewart, K. M., Horton, K. L. & Kelley, S. O. Mitochondria-penetrating peptides: sequence effects and model cargo transport. Chembiochem 10, 2081–2088 (2009).
  CAS PubMed Google Scholar
• Neupert, W. & Herrmann, J. M. Translocation of proteins into mitochondria. Annu. Rev. Biochem. 76, 723–749 (2007).
  CAS PubMed Google Scholar
• Mukhopadhyay, A., Ni, L., Yang, C. S. & Weiner, H. Bacterial signal peptide recognizes HeLa cell mitochondrial import receptors and functions as a mitochondrial leader sequence. Cell. Mol. Life Sci. 62, 1890–1899 (2005).
  CAS PubMed Google Scholar
• Vestweber, D. & Schatz, G. DNA–protein conjugates can enter mitochondria via the protein import pathway. Nature 338, 170–172 (1989).
  CAS PubMed Google Scholar
• Srivastava, S. & Moraes, C. T. Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease. Hum. Mol. Genet. 10, 3093–3099 (2001).
  CAS PubMed Google Scholar
• Horton, K. L., Stewart, K. M., Fonseca, S. B., Guo, Q. & Kelley, S. O. Mitochondria-penetrating peptides. Chem. Biol. 15, 375–382 (2008).
  CAS PubMed Google Scholar
• Maiti, K. K. et al. Guanidine-containing molecular transporters: sorbitol-based transporters show high intracellular selectivity toward mitochondria. Angew. Chem. Int. Ed. Engl. 46, 5880–5884 (2007).
  CAS PubMed Google Scholar
• Yamada, Y. et al. MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim. Biophys. Acta 1778, 423–432 (2008).
  CAS PubMed Google Scholar
• Weissig, V. et al. DQAsomes: a novel potential drug and gene delivery system made from dequalinium. Pharm. Res. 15, 334–337 (1998).
  CAS PubMed Google Scholar
• Galluzzi, L. et al. Methods to dissect mitochondrial membrane permeabilization in the course of apoptosis. Methods Enzymol. 442, 355–374 (2008).
  PubMed Google Scholar
• Deniaud, A. et al. Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene 27, 285–299 (2008).
  CAS PubMed Google Scholar
• Yamada, Y., Akita, H., Kogure, K., Kamiya, H. & Harashima, H. Mitochondrial drug delivery and mitochondrial disease therapy — an approach to liposome-based delivery targeted to mitochondria. Mitochondrion 7, 63–71 (2007).
  CAS PubMed Google Scholar
• Sergeeva, A., Kolonin, M. G., Molldrem, J. J., Pasqualini, R. & Arap, W. Display technologies: application for the discovery of drug and gene delivery agents. Adv. Drug Deliv. Rev. 58, 1622–1654 (2006).
  CAS PubMed PubMed Central Google Scholar
• Pathania, D., Millard, M. & Neamati, N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv. Drug Deliv. Rev. 61, 1250–1275 (2009).
  CAS PubMed Google Scholar
• Kitada, S. et al. Discovery, characterization, and structure–activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 46, 4259–4264 (2003).
  CAS PubMed Google Scholar
• Kirshner, J. R. et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol. Cancer Ther. 7, 2319–2327 (2008).
  CAS PubMed Google Scholar